April 15, 2026 · Form 4 insider transaction
REED ELIZABETH E sold 5,226 shares of Travere Therapeutics, Inc. at $41.62 per share, a transaction worth $217.5K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 0 days after the transaction.
This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.; The weighted average sale price for the transaction reported was $41.62, and the range of prices were between $41.255 and $42.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.